Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals Gets Help From Ology Bioservices and the Defense Department with Its COVID-19 Vaccine Candidate

By Prosper Junior Bakiny - Mar 24, 2020 at 5:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A $11.9 million Defense Department grant will support the companies as they develop and test INO-4800.

Inovio Pharmaceuticals (INO 0.93%) has received quite a bit of help in its quest to develop a vaccine for SARS-CoV-2, the coronavirus that causes COVID-19.

For instance, on Jan. 23, the Coalition for Epidemic Preparedness Innovations awarded a grant of up to $9 million to Inovio to fund pre-clinical and clinical development of its vaccine candidate, INO-4800. Also, on March 12, the company received a grant of $5 million from the Bill & Melinda Gates Foundation to test and scale up the manufacture of the Cellectra 3PSP, a smart device for the intradermal delivery of INO-4800. 

Now, Inovio is  teaming up with Ology Bioservices, a privately held company that focuses on the development and manufacturing of vaccines and biologics. The two biotech companies received a grant of $11.9 million from the U.S. Department of Defense to manufacture INO-4800. Given the urgency of the situation, Inovio and Ology Bioservices are expected to expedite the manufacture of INO-4800 and deliver some to the Defense Department for clinical trials as soon as possible.

Nurse holding test tube with blood for Coronavirus testing.

Image Source: Getty Images.

Inovio famously claimed that it created INO-4800 in just three hours after the genetic sequence of SARS-CoV-2 was made public by Chinese researchers on Jan. 10. The company expects to start its own clinical trials for the vaccine next month.

Meanwhile, other companies are pushing ahead in their attempts to develop a vaccine for COVID-19. Most notably, the U.S. National Institutes of Health is currently leading a phase 1 clinical trial for a potential SARS-CoV-2 vaccine that was developed by Moderna (MRNA 0.62%). The trial will enroll 45 healthy adult volunteers who will each receive two doses of the vaccine. The goals of the trial are to test the safety of the vaccine, its ability to trigger the body's immune response, and the dosage that causes expected side effects.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.96 (0.93%) $0.02
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$145.17 (0.62%) $0.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.